عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Design Space AlUla Celebrates Architectural Designs

Design space AlUla celebrates architectural designs. (SPA)
Design space AlUla celebrates architectural designs. (SPA)
TT
TT

Design Space AlUla Celebrates Architectural Designs

Design space AlUla celebrates architectural designs. (SPA)
Design space AlUla celebrates architectural designs. (SPA)

Design Space AlUla gallery, located in the heart of AlJadidah Arts District, has become a focal point for wide-ranging design initiatives, in line with AlUla's goal to support the Kingdom's thriving arts and culture scene, including students, design experts, and enthusiasts, SPA said on Monday.
Opened on February 15, Design Space AlUla hosts exhibitions in a contemporary building surrounding a luminous courtyard. The building, designed by the Italian studio Gio Forma, and inspired by the ancient, textured brick buildings commonly used in the surrounding buildings in AlJadidah neighborhood, is made of Corten steel (weathering steel), glass, and polished concrete.
Through a series of exhibitions and workshops overseen by Design Space AlUla's curator Eng. Sara Ghani, the gallery aims to get in touch with local and international design experts, and emerging designers, to discuss design principles and the stages of creative design. The space allows for the display of architecture, urban planning, production, and graphic design.
The gallery's opening exhibition, "Mawrid: Celebrating Inspired Design", is accompanied by a busy program of cultural and dialogue events. Mawrid, which will run until June 1, is the first exhibition among a series that will show.
The exhibition also explores the visual identity of Design Space AlUla, which was designed by Clara Sancho Studio and 29Letters design studio, and was inspired by AlUla's unique architecture.
Meanwhile, an exhibition designed by Atelier Brückner, a German architecture firm, takes the visitors on a sensorial trip through designs inspired by AlUla as well, bringing various designers' works in a captivating spatial narration.
The second edition of AlUla Design Award finalists are also participating in the exhibition.
According to Ghani: "Design Space AlUla celebrates AlUla's natural history and cultural heritage and enables a sustainable future rooted deep within the place. Our ambition is to support the design sector and provide resources for designers to explore and experiment. We aim to make this space a place that enables visitors to search, explore, and communicate with the stages of AlUla's design trip.
AlUla is creating an archive for all the creative projects, acting as a source of design inspiration and a compendium of local design initiative

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”